BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.48
-0.02 (-0.24%)
At close: Mar 6, 2026, 4:00 PM EST
8.60
+0.12 (1.42%)
After-hours: Mar 6, 2026, 7:37 PM EST

BioCryst Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2,1271,6621,5681,2332,1572,553
Market Cap Growth
9.35%5.97%27.23%-42.86%-15.51%93.75%
Enterprise Value
2,3291,8642,0891,6922,4762,640
Last Close Price
8.487.807.525.9911.4813.85
PE Ratio
7.016.45-17.49-5.08-8.63-13.45
Forward PE
35.8333.02----
PS Ratio
2.431.903.483.727.9716.25
PB Ratio
--13.95-3.30-2.71-7.32-23.87
P/TBV Ratio
-15.56-14.31-3.27-2.53-7.24-23.19
P/FCF Ratio
6.174.82-29.51-12.67-13.23-17.66
P/OCF Ratio
6.124.78-30.15-12.96-13.33-17.96
EV/Sales Ratio
2.662.134.635.119.1416.80
EV/EBITDA Ratio
6.645.45-1610.49-16.58-16.84-14.92
EV/EBIT Ratio
6.715.47-821.40-16.32-16.68-14.86
EV/FCF Ratio
6.755.41-39.30-17.39-15.18-18.27
Debt / Equity Ratio
-4.01-4.01-1.77-1.86-2.52-5.56
Debt / EBITDA Ratio
0.591.39-648.74-8.32-5.05-3.36
Debt / FCF Ratio
1.381.38-15.83-8.72-4.55-4.11
Net Debt / Equity Ratio
-1.70-1.70-1.09-1.01-1.08-0.81
Net Debt / EBITDA Ratio
0.250.59-401.36-4.50-2.17-0.49
Net Debt / FCF Ratio
0.590.59-9.79-4.72-1.95-0.60
Asset Turnover
2.671.740.890.620.480.34
Inventory Turnover
2.832.830.670.160.300.63
Quick Ratio
1.951.952.492.974.505.18
Current Ratio
2.062.062.633.314.905.46
Return on Equity (ROE)
-88.68%-88.68%19.08%60.40%123.07%291.59%
Return on Assets (ROA)
158.99%66.99%-0.52%-19.47%-26.38%-38.99%
Return on Invested Capital (ROIC)
1126.31%474.57%-10.65%-742.67%-7815.41%941.16%
Return on Capital Employed (ROCE)
249.73%105.22%-0.73%-25.56%-31.96%-49.82%
Earnings Yield
12.41%15.51%-5.72%-19.70%-11.59%-7.44%
FCF Yield
16.22%20.75%-3.39%-7.89%-7.56%-5.66%
Buyback Yield / Dilution
-0.53%-0.02%0.26%-0.53%-0.69%-2.58%
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q